Success Metrics

Clinical Success Rate
91.7%

Based on 11 completed trials

Completion Rate
92%(11/12)
Active Trials
0(0%)
Results Posted
27%(3 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
5
38%
Ph phase_3
2
15%
Ph phase_1
6
46%

Phase Distribution

6

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
6(46.2%)
Phase 2Efficacy & side effects
5(38.5%)
Phase 3Large-scale testing
2(15.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

84.6%

11 of 13 finished

Non-Completion Rate

15.4%

2 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(11)
Terminated(2)

Detailed Status

Completed11
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
91.7%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (46.2%)
Phase 25 (38.5%)
Phase 32 (15.4%)

Trials by Status

withdrawn18%
completed1185%
terminated18%

Recent Activity

0 active trials
Showing 5 of 13
completedphase_1

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

NCT00655655
completedphase_3

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

NCT00056459
completedphase_1

Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors

NCT00390000
completedphase_2

Vatalanib in Treating Patients With Recurrent or Progressive Meningioma

NCT00348790
completedphase_3

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

NCT00056446
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT00655655Phase 1

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Completed
NCT00056459Phase 3

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.

Completed
NCT00390000Phase 1

Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors

Completed
NCT00348790Phase 2

Vatalanib in Treating Patients With Recurrent or Progressive Meningioma

Completed
NCT00056446Phase 3

Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer

Completed
NCT00072475Phase 2

Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes

Completed
NCT00387933Phase 1

Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma

Completed
NCT00227773Phase 2

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Withdrawn
NCT00185588Phase 1

Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer

Completed
NCT00563823Phase 2

Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery

Completed
NCT00293371Phase 1

Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer

Terminated
NCT00128700Phase 1

Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed
NCT00590343Phase 2

Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13